DUBLIN--(BUSINESS WIRE)--The "Analysis of the APAC Cardiac Troponin Diagnostics Market, Forecast to 2021" report has been added to ResearchAndMarkets.com's offering.
Cardiac troponins will continue to remain the gold standard for early diagnosis of acute myocardial infarction (AMI); however, the key challenge to address is the advent of a complementary biomarker to prevent repeat diagnosis. Multiplexing platforms should be harnessed for simultaneous testing of complementary biomarkers such as H-FABP, cardiac myosin binding C protein, co-peptin, and Pentraxin 3 (PTX3) that should be combined with utmost clinical utility.
Chinese Food & Drug Administration (CFDA) and regional market access to APAC countries such as Indonesia and India will emerge as key markets with early commercial access with the new proposed CE regulatory guidelines that require lengthy approval times and clinical benefits. Furthermore, with the huge market opportunities in emerging APAC countries, unlike the conventional approach APAC market, access will take a center stage in parallel with Europe and the US.
There is a general trend toward decentralization of laboratory testing in hospitals that have demonstrated an overall improvement in operational efficiency by 30% to 40%, further supported by the overall trends in pathology price cuts as an indirect measure to rising healthcare expenditure. Given the overall market trends in central lab testing, there will be a higher propensity toward adoption of POCT, with quantitative outcomes for mainstream clinical diagnosis. There will be an increase in adoption of POCT, which would eventually shrink the lab-based market for troponin biomarkers used for the diagnosis of MI.
Physicians are demanding for a more accurate test which could reduce the burden in the healthcare settings. For patients under the acute critical conditions such as myocardial infarction, fast results and quick diagnosis are required. The rising prevalence of MI and increasing morbidity in the region will fuel the growth of diagnostic testings. Moreover, demands from physicians for more accurate and sensitive results will push researchers and investments for the diagnosis of MI.
Key Topics Covered
1. Executive Summary
2. Market Overview
3. Competitive Playbook
4. Driver and Restraints
5. Forecast and Discussion
6. Competitive Environment
7. Growth Opportunities
8. Lab-based Segment Analysis
9. POCT Segment Analysis
10. The Last Word
11. Appendix
For more information about this report visit https://www.researchandmarkets.com/research/fm4rmw/analysis_of_the?w=4
